Conivaptan Hydrochloride

盐酸考尼伐坦

Report date: 2026/05/11 20:01:57
NMEFirst In Class

Base Information

Drug NameConivaptan Hydrochloride
Drug Alias Name考伐普坦Conivaptanum盐酸科尼法坦可尼普坦考尼伐坦 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V1a receptor antagonistsVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptorVasopressin V1a receptor
Therapy Area/IndicationsAcutely decompensated congestive heart failureHyponatremiaHeart Failure +[7] 
Global Approved IndicationsHyponatremia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/12/29
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesCumberland Pharmaceuticals IncJiangsu Wangao Pharmaceutical Co LtdBeijing Collab Pharm Co Ltd +[4] 
Inactive CompaniesAstellas Pharma Us IncColumbia UniversityAstellas Pharma Inc +[4] 
Active IndicationsHyponatremia
Inactive IndicationsAcutely decompensated congestive heart failureHeart FailureKidney Diseases +[6] 

Other Information

ATC CodeC03XA02
Related LinksWikipediaDrugBankKEGG